ARTICLE | Emerging Company Profile
Clade: immune-cloaked, iPSC-derived cell therapies
Syncona’s first allogeneic cell therapy investment goes to Clade, led by Sana and CRISPR Therapeutics co-founder Cowan
December 22, 2021 1:55 AM UTC
After licensing an immune-silent technology to cell therapy company Sana from his Harvard lab in 2019, professor Chad Cowan is now leading Clade, a start-up that has assembled an immune-cloaking tool kit that can enhance the persistence of its iPS cell-derived treatments.
Clade Therapeutics Inc. is the first investment by Syncona Ltd. (LSE:SYNC) in an allogeneic cell therapy company. The U.K. firm led the start-up’s $87 million series A round in November, joining LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb Co. (NYSE:BMY)...
BCIQ Company Profiles